Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis Inc (CDXS) pioneers enzyme engineering solutions for biopharmaceutical manufacturing through its CodeEvolver and ECO Synthesis platforms. This page aggregates all official announcements and developments critical to understanding the company's trajectory.
Investors and industry professionals will find curated updates including earnings reports, strategic partnerships, product launches, and manufacturing innovations. Our collection ensures timely access to material information affecting therapeutic production efficiency.
Key content categories include financial performance disclosures, technology licensing agreements, enzyme optimization breakthroughs, and sustainability initiatives. All updates are sourced directly from verified corporate communications.
Bookmark this page for streamlined tracking of Codexis' advancements in protein engineering and RNA therapeutic manufacturing. Check regularly for developments impacting biotech production economics and pharmaceutical process optimization.
Codexis has appointed Karen Frechou-Armijo as Senior Vice President of Human Resources and Asli Aras, Ph.D., as Vice President of Corporate Development. Frechou-Armijo brings extensive HR experience, previously growing employee numbers at Cepheid significantly. Dr. Aras, with a strong background in corporate development, will enhance Codexis’ inorganic growth strategy. Both executives report to John Nicols, President and CEO, who emphasized their roles in building a high-performance culture and advancing growth opportunities as Codexis prepares for a crucial year ahead.
Codexis (Nasdaq:CDXS) announced key presentations at the 14th International Congress of Inborn Errors of Metabolism 2021, highlighting potential treatments for homocystinuria and maple syrup urine disease. The oral presentations will take place on November 21, 2021, featuring CDX-6512, a methionine-gamma-lyase enzyme therapy for homocystinuria, and a bacterial leucine decarboxylase therapy for maple syrup urine disease. Both will be presented by Dr. Kristen Skvorak, emphasizing innovative drug development efforts by Codexis to leverage synthetic biology.
Codexis (Nasdaq: CDXS) announced participation in three upcoming virtual investment conferences on November 16-18, 2021, showcasing its leading enzyme engineering capabilities. The events include the 12th Annual Craig-Hallum Alpha Select Conference, the Stifel 2021 Virtual Healthcare Conference, and the Jefferies London Healthcare Conference with scheduled 1x1 meetings and fireside chats. Webcasts will be available on Codexis' Investor Relations webpage for 30 days post-event. Codexis' innovations in enzyme technology aim to enhance sustainable manufacturing and biotherapeutics.
Codexis, Inc. (Nasdaq:CDXS) reported impressive financial results for Q3 2021, with total revenues reaching $36.8 million, a 100% increase from Q3 2020. Product revenues surged 242% to $28.7 million, driven by significant enzyme sales for Pfizer's COVID-19 antiviral candidate. The company achieved a record product gross margin of 76%. Codexis reiterated its total revenue guidance for FY 2021 at $98-103 million and raised product revenue guidance to $63-66 million. The company continues to expand its collaborations, including new agreements with Merck and Kalsec.
Codexis (CDXS) announced a $10 million investment in Molecular Assemblies, Inc. (MAI) through the SynBio Innovation Accelerator, aimed at accelerating MAI's enzymatic DNA synthesis technology. This partnership, initiated in June 2020, seeks to make DNA synthesis more cost-effective.
Codexis is the second largest shareholder in MAI and has a board seat. The investment highlights Codexis' commitment to pioneering solutions in synthetic biology, necessary for enhancing DNA synthesis capabilities. The SynBio Innovation Accelerator supports early-stage companies with disruptive technologies in synthetic biology.
Codexis (NASDAQ: CDXS) has commenced a Phase 1 study for its novel biotherapeutic, CDX-7108, in collaboration with Nestlé Health Science. This enzyme aims to address exocrine pancreatic insufficiency (EPI) caused by conditions like pancreatitis and cystic fibrosis. The study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics through a randomized, double-blind trial with healthy subjects and EPI patients. This partnership leverages Codexis’ enzyme engineering platform for innovative therapies, signaling a significant advancement in treatment options for EPI patients.
Codexis (Nasdaq: CDXS) will report its third quarter 2021 financial results on November 4, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET, where management will discuss the results and provide a business update. The call can be accessed domestically at 866-682-6100 and internationally at 862-298-0702, using conference ID #13724176. Codexis leverages its CodeEvolver® platform to develop high-performance enzymes for various applications, emphasizing sustainability and efficiency.
Codexis (CDXS) has entered a tri-party collaboration agreement with Almelo Private and RC2 Pharma Connect to license and use Codexis' proprietary enzyme for manufacturing sitagliptin, an active pharmaceutical ingredient for diabetes treatment. Almelo will develop and optimize the commercial manufacturing process, while RC2 will enhance supply chain efficiency for the future generic sitagliptin market. This partnership aims to reduce costs and improve production sustainability, positioning all parties for success in a competitive market.
Codexis (Nasdaq: CDXS) announced an extension of its agreement with Merck to license and supply a proprietary enzyme used in the manufacturing of sitagliptin, the API in Merck’s JANUVIA® and JANUMET®. This partnership, which has lasted over a decade, will now extend through December 31, 2026, with a potential 5-year renewal. The enzyme enhances manufacturing efficiency, reducing costs and waste. Codexis and Merck previously won the EPA's Presidential Green Chemistry Challenge Award for their innovative manufacturing method.
Codexis (Nasdaq:CDXS), an enzyme engineering leader, announced its participation in two virtual investment conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will take place on September 13, 2021, featuring an on-demand corporate presentation. Following that, the Cantor Virtual Global Healthcare Conference is scheduled for September 28, 2021, with a fireside chat at 10:40 a.m. ET. Webcasts of both events will be available on the Company's Investor Relations website for 90 days post-event, highlighting Codexis' advancements in synthetic biology and enzyme technology.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
